{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:07:05Z","timestamp":1771538825331,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005081","name":"Beijing Council of Science and Technology","doi-asserted-by":"publisher","award":["Z171100001017188"],"award-info":[{"award-number":["Z171100001017188"]}],"id":[{"id":"10.13039\/501100005081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Azacitidine is commonly used in the treatment of relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the effectiveness of this monotherapy is still very low. A possible mechanism of resistance to hypomethylating agents (HMAs) is the upregulation of the expression of inhibitory checkpoint receptors and their ligands, making the combination of HMAs and immune checkpoint blockade therapy a rational approach. Although the safety of anti-programmed cell death protein (PD)-1 antibodies for patients with post-allo-HSCT remains a complicated issue, the preliminary clinical result of combining azacitidine with anti-PD-1 antibodies is encouraging; however, the safety and efficacy of this approach need further investigation.<\/jats:p><jats:p><jats:bold>Case Presentation:<\/jats:bold>We reported a case of treated secondary (ts)-AML in a patient who received tislelizumab (an anti-PD-1 antibody) in combination with azacitidine. The patient relapsed after allo-HSCT and was previously exposed to HMAs-based therapy. The patient received tislelizumab for compassionate use. After the combination treatment, the patient achieved complete remission with incomplete hematologic recovery, negative minimal residual disease (MRD) by flow cytometry (FCM), and negative Wilms' tumor protein 1 (WT1). However, the patient successively developed serious immune-related adverse events (irAEs) and graft vs. host disease (GVHD) and eventually died from complications of GVHD.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>To our knowledge, this is the first case to report the combined use of tislelizumab and azacitidine to treat relapsed AML posttransplantation. This report highlights the safety concerns of using an anti-PD-1 antibody in combination with azacitidine after allo-HSCT, especially the risk of GVHD, and provides a basis for future studies.<\/jats:p>","DOI":"10.3389\/fimmu.2021.639217","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T04:56:55Z","timestamp":1617253015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD"],"prefix":"10.3389","volume":"12","author":[{"given":"Sun","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jianlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Zhuoqing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yuhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Jiangwei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Guoliang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Hongmei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Bin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Liangding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","article-title":"Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Oran","year":"2007","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bbmt.2010.12.713","article-title":"National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee","volume":"17","author":"Bishop","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.bbmt.2013.08.016","article-title":"Proceedings from the national cancer institute's second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: introduction","volume":"19","author":"Wayne","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B4","unstructured":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study4549 BejanyanN WeisdorfDJ LoganBR WangH-L DevineSM de LimaM 25460355Biol Blood Marrow Transpl.212015"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood.V116.21.2186.2186","article-title":"A retrospective study of decitabine for the treatment of relapsed or refractory acute myeloid leukemia: lack of response observed in a heavily pretreated population","volume":"116","author":"George","year":"2010","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"B8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.Cd-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/hematology.2019000005","article-title":"Clonal evolution and immune evasion in posttransplantation relapses","volume":"2019","author":"Vago","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.Ccr-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V128.22.2900.2900","article-title":"Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.4049\/jimmunol.162.11.6368","article-title":"Opposing roles of CD28:B7 CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells","volume":"162","author":"Blazar","year":"1999","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-vs.-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood-2010-04-283119","article-title":"PD-L1 blockade effectively restores strong graft-vs.-leukemia effects without graft-vs.-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells","volume":"117","author":"Koestner","year":"2011","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/bmt.2016.346","article-title":"Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation","volume":"52","author":"McDuffee","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41409-019-0498-0","article-title":"The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma","volume":"54","author":"Holderried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cncr.25598","article-title":"Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome","volume":"117","author":"Bello","year":"2011","journal-title":"Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1365-2141.2012.09076.x","article-title":"Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure","volume":"157","author":"Pr\u00e9bet","year":"2012","journal-title":"Br J Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.16354","article-title":"How to address second and therapy-related acute myelogenous leukaemia","volume":"188","author":"Oliai","year":"2020","journal-title":"Br J Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/blood-2018-99-112310","article-title":"Nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation (NIVALLO)","volume":"132","author":"Wong","year":"2018","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1182\/blood.V128.22.4571.4571","article-title":"Checkpoint inhibitor therapy and graft vs. host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post-transplant cyclophosphamide","volume":"128","author":"Schoch","year":"2016","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.bbmt.2020.01.021","article-title":"Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transpl."},{"key":"B33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/bmt.2016.274","article-title":"PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation","volume":"52","author":"Albring","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.Ccr-17-2777","article-title":"Ipilimumab plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies","volume":"24","author":"Khouri","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/bmt.2017.44","article-title":"Nivolumab before and after allogeneic hematopoietic cell transplantation","volume":"52","author":"Covut","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"26257","DOI":"10.1002\/pbc.26257","article-title":"Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report","volume":"64","author":"Shad","year":"2017","journal-title":"Pediatr Blood Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann Hematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-017-0211-z","article-title":"PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Godfrey","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/bmt.2017.107","article-title":"MRD response in a refractory paediatric T-ALL patient through antiprogrammed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD","volume":"52","author":"Boekstegers","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","article-title":"Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma","volume":"52","author":"El Cheikh","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/bmt.2015.346","article-title":"Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-vs.-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4049\/jimmunol.1102630","article-title":"Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-vs.-host disease","volume":"188","author":"Li","year":"2012","journal-title":"J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000471768","article-title":"Potential role of the PD-1\/PD-L1 axis in the immune regulation of chronic GVHD","volume":"40","author":"Klobuch","year":"2017","journal-title":"Oncol Res Treat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrgastro.2017.126","article-title":"Acute graft-vs.-host disease of the gut: considerations for the gastroenterologist","volume":"14","author":"Naymagon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R? has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1172\/jci85796","article-title":"Programmed death ligand-1 expression on donor T cells drives graft-vs.-host disease lethality","volume":"126","author":"Saha","year":"2016","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.639217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:34:58Z","timestamp":1698842098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.639217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2021.639217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.639217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"article-number":"639217"}}